Relying on an ultra-rare variant, David Liu unveils a new approach to editing sickle cell

Jason Mast

Editor

There are now at least five different approaches to curing sickle cell in or nearing human testing from at least eight different companies or academic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Relying on an ultra-rare variant, David Liu unveils a new approach to editing sickle cell

Jason Mast

Editor

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

When generative AI meets the FDA: First digital health adcomm kicks off discussion

Pfizer partners with two more Flagship biotechs on obesity, cancer

Are programs with compounded GLP-1s safe for your population?

Re­ly­ing on an ul­tra-rare vari­ant, David Liu un­veils a new ap­proach to edit­ing sick­le cell

Jason Mast

Editor

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Relying on an ultra-rare variant, David Liu unveils a new approach to editing sickle cell

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

When generative AI meets the FDA: First digital health adcomm kicks off discussion

Pfizer partners with two more Flagship biotechs on obesity, cancer

Are programs with compounded GLP-1s safe for your population?